Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > ADAM17


Brief Information

Name:Disintegrin and metalloproteinase domain-containing protein 17
Target Synonym:EC:,ADAM17 Protein,ADAM 17,Snake venom-like protease,CSVP,CD156b,ADAM17,ADAM Metallopeptidase Domain 17,TNF-Alpha Convertase,TACE,TNF-Alpha Converting Enzyme,TNF-Alpha-Converting Enzyme,CD156b Antigen,EC,NISBD1,NISBD,Disintegrin and metalloproteinase domain-containing protein 17,Tumor Necrosis Factor, Alpha, Converting Enzyme,ADAM Metallopeptidase Domain 18,ADAM18
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
AD7-M52H1 Mouse Mouse ADAM17 / TACE / CD156b Protein, His Tag
ACRO Quality

Synonym Name



Disintegrin and metalloproteinase domain-containing protein 17 (ADAM17), a member of the ADAM protein family of disintegrins and metalloproteases, is also known as TNF-alpha convertase, TNF-alpha-converting enzyme and CD156b, which contains one disintegrin domain and one peptidase M12B domain. ADAM17 can cleave the membrane-bound precursor of TNF-alpha to its mature soluble form. ADAM17 is also responsible for the proteolytical release of soluble JAM3 from endothelial cells surface (By similarity) and proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein. Furthermore, ADAM17 acts as an activator of Notch pathway by mediating cleavage of Notch, generating the membrane-associated intermediate fragment called Notch extracellular truncation.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Aderbasib INCB-7839; INC-B007839; INCB-007839 Phase 2 Clinical Incyte Corp Solid tumours; Neoplasms; Glioblastoma; Lymphoma, Large B-Cell, Diffuse; Oligodendroglioma; Breast Neoplasms; Astrocytoma; Diffuse Intrinsic Pontine Glioma; Glioma Details
ORYN-1001 ORTD-1; ORYN-1001 Phase 1 Clinical Oryn Therapeutics Llc Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message